Cyclin-dependent kinases (CDKs) are important in regulating cell cycle transitions, particularly in coordinating DNA replication. Although the role of CDK2 activity on the replication apparatus has been extensively studied, the role of CDK4/6 in DNA replication control is less understood. Through targeted inhibition of CDK4/6 activity, we demonstrate that CDK4/6 kinase activity promotes cdc6 and cdt1 expression, and pre-replication complex (pre-RC) assembly in cycling cells. Conversely, CDK2 inhibition had no effect on the pre-RC assembly. The inhibition of pre-RC assembly is dependent on a functional retinoblastoma (RB) protein, which mediates downstream effects. As such, CDK4/6 inhibition has minimal effect on the replication apparatus in the absence of RB. The requirement of CDK4/6 was further interrogated using cells lacking D-type cyclins, in which replication complexes form normally, and correspondingly CDK4/6 inhibition had no effect on cell cycle or replication control. However, in the absence of D-type cyclins, CDK2 inhibition resulted in the attenuation of cdc6 and cdt1 levels, suggesting overlapping roles for CDK4/6 and CDK2 in regulating replication protein activity. Finally, CDK4/6 inhibition prevented the accumulation of cdc6 and cdt1 as cells progressed from mitosis through the subsequent G 1 . Combined, these studies indicate that CDK4/6 activity is important in regulating the expression of these critical mediators of DNA replication.
Introduction
Cyclin-dependent kinases (CDKs) are important in cell proliferation. As eukaryotic cells progress through the cell cycle, CDK/cyclins phosphorylate a myriad of proteins crucial to cells entering each cell cycle stage. In G 1 , CDK4/6 partners with D-type cyclins (D1, D2 and D3) to form a catalytically active complex, which functions to phosphorylate the retinoblastoma (RB) tumor suppressor (Sherr, 1996; Sherr and Roberts, 1999) . As cells enter into S phase, CDK2/cyclin E and CDK2/cyclin A activity accumulates (Koff et al., 1991 (Koff et al., , 1992 Hwang and Clurman, 2005) , ultimately leading to phosphorylation of several proteins needed for S-phase entry and subsequent DNA replication (Woo and Poon, 2003) . Finally, as cells pass through G 2 , high levels of CDK1/cyclin B promotes entry into mitosis, whereas subsequent degradation of cyclins A and B mediates mitotic exit (Sherr, 1996; Sullivan and Morgan, 2007) .
CDK4/6 activity is positively regulated through mitogenic signaling (Diehl, 2002; Knudsen et al., 2006) and negatively regulated by stresses that inhibit G 1 progression (Sherr and Roberts, 1999; Sherr, 2001) . The induction of cyclin D1 expression is a delayed early response to mitogens and expression during G 1 is critical for initiating cell cycle progression from quiescence. Under favorable growth conditions, CDK4/6/cyclin D complexes phosphorylate RB, allowing for the release of the transcription factor E2F, and subsequent transcription of E2F target genes (for example, cyclins E and A) (Palmero and Peters, 1996; Sherr, 1996 Sherr, , 2000 Bartek et al., 1997; Bartkova et al., 1997; Sherr and McCormick, 2002) . The accumulation of cyclin E contributes to the activation of CDK2, which further phosphorylates RB and promotes S phase entry (Hwang and Clurman, 2005) . As cells progress into S phase, high levels of cyclin A are involved in DNA replication control (Angus et al., 2004; Braden et al., 2006) . DNA replication is a highly ordered process that ensures cells replicate their genome only once per cell cycle (Diffley, 1994; Bell and Dutta, 2002; Blow and Hodgson, 2002; Diffley and Labib, 2002; Dimitrova et al., 2002) . In the accepted model, two proteins, cdc6 and cdt1, are individually recruited to the origin recognition complex in late telophase before cells enter G 1 of the subsequent cell cycle (Dutta and Bell, 1997; Stillman, 2005) . Together, these proteins serve as a scaffold and are required to recruit mini-chromosome maintenance (MCM) proteins, MCM2-7 (Dimitrova et al., 1999; Mendez and Stillman, 2000; Okuno et al., 2001; Diffley and Labib, 2002) . A large body of evidence suggests that cdc6 and cdt1 are essential for MCM loading, and that loss of either protein will result in the cessation of replication. Once MCMs are bound, this complex is termed the pre-replication complex (pre-RC), and origins are licensed for replication due to the helicase activity associated with MCMs (Dimitrova et al., 1999 (Dimitrova et al., , 2002 Mendez and Stillman, 2000; Diffley and Labib, 2002; Diffley, 2004; Stillman, 2005) . MCMs are necessary for DNA replication and disruption of any one of the subunits in the hexameric ring will prevent further replication factor recruitment (Labib et al., 2000 (Labib et al., , 2001 . The pre-RC will in turn recruit cdc45 and MCM10 to become the pre-initiation complex as cells transition into S phase (Diffley and Labib, 2002) . A multitude of additional factors are then recruited (that is, replication factor C (RFC), replication protein A, proliferating cell nuclear antigen (PCNA) and polymerase) to form the fully competent replisome, primed for genome duplication (Diffley and Labib, 2002) .
For replication origins to become active, the pre-RC is modified at the G 1 /S transition by CDK2 and cdc7-dbf4 (Lei et al., 1997; Blow and Hodgson, 2002; Coverley et al., 2002) . Interestingly, these same kinases phosphorylate the pre-RC to prevent further origin firing (Dahmann et al., 1995; Hua et al., 1997; Noton and Diffley, 2000) ; however, the exact mechanism(s) underlying this regulation remains unclear. The paradoxical regulation of the pre-RC by CDKs has been termed the 'replication switch', in which basal CDK activity in early G 1 is sufficient to license the pre-RC, whereas high levels of CDKs prevent formation of new pre-RCs and origin refiring (Blow and Hodgson, 2002) . Early studies demonstrated that high levels of CDK2 function to prevent pre-RC assembly and further MCM recruitment once cells have entered into S phase to prevent re-replication. More recently, it has been shown that not only does CDK2 negatively regulate cdc6 expression in S phase, but CDK2 activity stabilizes cdc6 in G 1 . Despite these findings relating CDK2 or cyclin E to pre-RC assembly, the role of CDK4/6 function on the pre-RC has not been explored in detail.
Here we sought to determine the action of CDK4/6 activity on replication dynamics. Our findings indicate that CDK4/6 function is required for pre-RC assembly. Specifically, CDK4/6 inhibition was found to inhibit the expression of cdc6 and cdt1, preventing MCM chromatin loading. A functional RB pathway is required for CDK4/6 to influence the pre-RC, thus facilitating downregulation of cdc6 and cdt1, as well as the attenuation of CDK2 activity. These findings were further supported by a cell system expressing no D-type cyclins in which CDK2 inhibition disrupted pre-RC formation. Interestingly, when CDK4/6 activity was inhibited in mitosis, cells entered the subsequent G 1 , but were unable to form new pre-RCs, suggesting CDK4/6 is involved in replication apparatus assembly as cells progress through the cell cycle. Combined, these studies provide new insight into the complex role of CDK/ cyclin activity in regulating DNA replication.
Results
Targeted CDK4/6 inhibition elicits a G 1 cell cycle arrest and prevents pre-RC loading To investigate the specific role of CDK4/6 activity in pre-RC assembly, a small molecule inhibitor of CDK4/6, PD-332991 (Pfizer), was utilized. PD-332991 has been shown to selectively inhibit CDK4/6 without affecting CDK1, CDK2 or CDK5 activity (Fry et al., 2004) . In U2OS (human osteosarcoma) cells, PD-332991 treatment elicited significant cell cycle inhibition (Figure 1a) . The CDK2 inhibitor, roscovitine, also inhibited cell cycle progression, albeit to a lesser extent (Figure 1a ). To determine if this arrest involved the disruption of DNA replication apparatus, members of the replication machinery were examined. Chromatinassociated MCM7 was disrupted by PD-332991 (Figure 1b) , as was PCNA chromatin retention ( Figure 1c) . Consistent with previously published results, roscovitine treatment disrupted PCNA chromatin association (Figure 1c) , although having no effect on MCM7 chromatin levels (Figure 1b) (Savio et al., 2006) . It is known that MCM chromatin loading is dependent on cdc6 and cdt1 origin binding. To determine if this loss of MCM loading was dependent on cdc6 and cdt1 expression, total protein of these two pre-RC components was examined. When U2OS cells were treated with PD-332991, cdc6 and cdt1 expression was downregulated (averages of sixfold and fourfold, respectively), whereas roscovitine treatment had minimal effects on cdc6 and cdt1 levels ( Figure 1d ). PD-332991 treatment also resulted in hypophosphorylation of RB and downregulation of the E2F target genes, cyclin A and CDK2 (Figure 1d ). However, CDK4/6 inhibition did not affect expression of the CDK2 inhibitor p27KIP1. Since CDK4/6 inhibition via PD-332991 led to the downregulation of CDK2 expression, PD-332991 would be expected to indirectly inhibit CDK2 kinase activity. To test this hypothesis, cells were treated with PD-332991 or transduced with adenovirus to p16ink4a and examined for CDK2-dependent histone H1 phosphorylation. Indeed, PD-332991 treatment resulted in a marked decrease in CDK2 kinase activity (data not shown). To further elucidate the mechanism by which inhibition of CDK4/6 influences pre-RC formation, the transcription and protein stability of cdc6 and cdt1 were examined. RNA levels of both cdc6 and cdt1 were decreased in U2OS cells treated with PD-332991 (Figure 1e ). In addition, stabilization of these proteins with the proteosome inhibitor MG132 resulted in a restoration of cdc6 and cdt1 protein levels in the face of CDK4/6 inhibition ( Figure 1f) . Thus, the reduction in RNA levels and relatively unstable nature of cdc6 and cdt1 proteins coalesce to mediate the downregulation of the proteins. From these results, we conclude that CDK4/6 activity is required for MCM7 loading onto the pre-RC, and that this effect is proximally dependent on the inhibition of cdt1 and cdc6 expression.
CDK4/6 dependent inhibition of the pre-RC requires a functional RB pathway It is well established that the primary target of CDK4/6 phosphorylation is the RB tumor suppressor protein. CDK4/6 functions to inactivate RB, releasing E2F transcription factors, resulting in the transcription of genes necessary for progression into S phase.
To determine if signaling through RB was required for CDK4/6-associated inhibition of the pre-RC, Saos-2 cells (RB negative) were treated with PD-332991 and roscovitine. As shown in Figure 2a , PD-332991 had very little effect on cell cycle progression, whereas roscovitine treatment significantly impeded progression into S phase. To determine if CDK4/6-associated kinase activity was necessary for pre-RC loading, Saos-2 cells were treated with PD-332991 or roscovitine-and chromatin-associated levels of MCM7 and PCNA were examined. Although neither compound had a significant effect on MCM7 loading (Figure 2b ), roscovitine was able to inhibit PCNA tethering (Figure 2c ), in agreement with previous studies that demonstrate CDK2-associated kinase activity directly regulates PCNA chromatin association (Sever-Chroneos et al., 2001) . In addition, neither compound had a significant effect on cdc6 or cdt1 expression in the absence of RB (Figure 2d ). Correspondingly, there is no attenuation of cdc6 or cdt1 RNA levels with PD-0332991 treatment in RB-deficient cells, demonstrating that this regulation is RB dependent (Figure 2e ). Strikingly, treatment of Saos-2 cells with MG132 results in a massive induction of cdc6 and cdt1 protein levels, indicating that, regardless of RB status, cdc6 and cdt1 are relatively unstable proteins. If PD-332991 were inhibiting CDK4/ 6, but not CDK2 activity as a consequence of the loss of RB, one would expect no change in CDK2-associated After treatment, cells were lysed, proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and the indicated proteins were detected by immunoblotting. (e) U2OS cells were treated with PD-332991 or DMSO for 24 h, RNA was isolated, cDNAs were generated and reverse transcriptase (RT)-PCR was performed using primers to amplify cdc6, cdt1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (f) U2OS cells were treated with PD-332991, DMSO and/or MG132 for 24 h. After treatment, cells were lysed, proteins were resolved by SDS-PAGE and the indicated proteins were detected by immunoblotting.
kinase activity. Indeed, phosphorylation of histone H1 was unchanged in the presence of PD-332991 or p16ink4a (data not shown). Combined, these results indicate that a functional RB pathway is required to inhibit pre-RC loading, and suggest that this association is likely dependent on both CDK4/6 and CDK2 kinase activity and the capacity to downregulate cdc6 and cdt1 expression.
To further interrogate the influence of RB in response to CDK4/6-mediated pre-RC inhibition, U2OS cells were transduced with retrovirus encoding a shorthairpin RNA against RB. Three days after selection, RB protein could not be detected in these cells ( Figure 3a ). When treated with PD-332991, cells expressing a scrambled hairpin (shDON) elicited a strong arrest in G 1 of the cell cycle (Figure 3b ), as well as a decrease in RB target gene expression (Figure 3c ), whereas those cells in which RB had been knocked down elicited a modest decrease in BrdU incorporation ( Figure 3b ) and no change in protein expression of RB targets (Figure 3c ). In concordance with these observed effects on cell cycle, MCM7 chromatin binding was significantly attenuated with PD-332991 in RB-proficient cells, whereas only marginally downregulated in RB-deficient cells (Figure 3d ). From these results we conclude that the effects of CDK4/6 on the pre-RC are RB dependent and not via direct interaction.
Loss of D-type cyclins sensitize cells to CDK2-mediated cell cycle arrest and pre-RC disruption Although the preceding pharmacological studies support an important role for CDK4/6 in modulating pre-RC assembly, a genetic model was utilized to further interrogate this action of CDK4/6. For these studies, murine fibroblasts derived from the D1, D2, and D3 triple knockout (TKO) animal were utilized (kindly provided by Dr Piotr Sicinski). These TKO cells have been immortalized by the use of a dominant negative p53 (Kozar et al., 2004) and were utilized to address the specific influence of D-type cyclins. As expected, TKO cells express no D-type cyclins compared with matched wild-type (WT) murine fibroblast cultures (Figure 4a ). In addition, these cells have been shown to progress through the cell cycle independently of CDK4/6-associated activity (Kozar et al., 2004) . When treated with PD-332991, WT cells elicited a significant G 1 arrest, whereas TKO cells did not respond to CDK4/6 inhibition ( Figure 4b ). To determine if PD-332991 was disrupting DNA replication in TKO cells, BrdU incorporation assays were performed. Although WT cells responded to both PD-332991 and roscovitine, exhibiting a decrease in DNA replication (Figure 4c ), TKO cells responded only to roscovitine treatment (Figure 4c ). This finding suggests that not only is CDK4/6 the sole target of PD-332991, but in this system, CDK2 is the predominant kinase modulating replication apparatus assembly.
To interrogate the impact of D-type cyclin deletion on the replication apparatus, WT and TKO cells were treated with the CDK2 inhibitor roscovitine for 24 h. Although roscovitine had no effect on cdc6 and cdt1 in WT cells, roscovitine-treated TKO cells exhibited a marked decrease in cdc6 and cdt1 protein expression (Figure 5a ). To determine if diminished cdc6 and cdt1 protein levels affected chromatin loading of replication factors, MCM7 chromatin retention was analysed. In the presence of roscovitine, chromatin-associated levels of MCM7 were not affected, whereas chromatinassociated PCNA was greatly diminished (Figure 5b) . Interestingly, in TKO cells that lack CDK4/6 activity, roscovitine disrupted both MCM7 and PCNA chromatin association (Figure 5b ). MCM7 and PCNA chromatin association was disrupted at 10 mM in TKO cells, whereas even higher doses did not affect MCM7 tethering in WT cells (Figure 5c ). These results confirm that MCM loading is dependent on cdc6 and cdt1 expression, and that CDK4/6 and CDK2 cooperate in regulating pre-RC assembly.
CDK4/6 activity is required for accumulation of licensing factors and S phase entry Pre-RCs assemble as cells exit mitosis, in a stage of the cell cycle when no mitotic CDK activity is present, and before CDK2 activity begins to rise. However, it is apparent that nuclear cyclin D1 is present in mitotic cells and contributes to facets of G 1 control (Yang et al., 2006) . To assess the formation of new pre-RCs, U2OS cells were treated with nocodazole to enrich for mitotic populations. Cells were then subjected to mitotic shakeoff and replated in the presence or absence of PD-332991. In the absence of PD-332991, mitotic cells could progress into the subsequent G 1 and S phases; however, treatment with PD-332991 resulted in continued arrest with a 2N DNA content (Figure 6a) . Furthermore, the expression of cdt1 and cdc6 was specifically attenuated in PD-332991 treated cells (Figure 6b ). To investigate the temporal coordination of cdt1 and cdc6 expression and cell cycle progression, cells were harvested at various time points following mitotic shake-off. As shown in Figure 7a , cells reenter the subsequent G 1 phase within 2 h post-mitotic shake-off, and this occurs irrespective of PD-332991 treatment. However, although there is a significant accumulation of phosphorylated RB in the absence of PD-332991 by 2 h postmitotic shake-off, RB remains unphosphorylated in the PD-332991 treated cells (Figure 7b ). This finding is consistent with previous studies demonstrating that RB phosphorylation is only modestly reduced following mitotic progression in U2OS cells, and suggests that the maintenance of RB phosphorylation during this transition is CDK4/6 dependent (Broceno et al., 2002) . Protein levels of cdt1 and cdc6 are detectable within 2 h following plating (Figure 7c) , and the accumulation of cdt1 and cdc6 was dependent on CDK4/6 activity, as PD-332991 resulted in a consistent decrease in both proteins. These findings indicate that CDK4/6 is important in S phase entry and mediating the accumulation of these critical licensing factors following mitotic exit.
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Discussion
The activity of CDK/cyclin complexes is critical for the initiation DNA replication. It is well established that CDK activity is important in suppressing re-replication of the genome by inhibiting reinitiation of DNA replication during S phase and latter phases of the cell cycle (Hua et al., 1997; Coverley et al., 2002; EkholmReed et al., 2004; Mimura et al., 2004) . Much of the emphasis regarding CDK activity and positive regulation of replication has focused on roles for CDK2 in modulating the firing of origins in S phase. However, we and others have recently found that CDK/cyclin activity is important in establishing the pre-RC in G 1 (Mailand and Diffley, 2005; Braden et al., 2006; Geng et al., 2007) . Specifically, the accumulation of both cdt1 and cdc6, which mediate the assembly of the MCM complex on chromatin, are influenced by the activity of CDK/ cyclins. Here we extend these prior findings by demonstrating that CDK4/6 activity is important in modulating the levels of cdt1 and cdc6 to facilitate the establishment of the pre-RC. A multitude of studies have analysed the importance of CDK2 activity in modulating DNA replication. These studies have suggested an important role for this kinase in stimulating the initiation of S phase and replication origin firing. Consistent with previous studies from our laboratory and others, we find that inhibition of CDK2 activity does not influence the loading of MCM proteins on chromatin, nor the expression of cdt1 and cdc6, which are required for pre-RC assembly (Braden et al., 2006; Savio et al., 2006) . However, inhibition of CDK2 activity does inhibit ongoing replication in S phase as determined by retention of PCNA on chromatin (Sever-Chroneos et al., 2001; Angus et al., 2004; Braden et al., 2006; Savio et al., 2006) . Thus, it is becoming increasingly clear that assembly of the pre-RC is independent of CDK2 activity. Strikingly, inhibition of CDK4/6 activity results in the strong suppression of cdt1 and cdc6 protein levels and a corresponding loss of chromatin-associated MCM proteins. In this context, previous studies have shown that ectopic expression of cdt1 and cdc6 allows for pre-RC assembly even with CDK activity inhibited, indicating a causal function for these factors (Mailand and Diffley, 2005; Braden et al., 2006) . However, restoration of pre-RC assembly is not sufficient to stimulate DNA replication due to additional requirements for CDK activity in the initiation and progression Figure 7 Cyclin-dependent kinase 4/6 (CDK4/6) activity is required for pre-replication complex (pre-RC) assembly in telophase. U2OS cells were treated with nocodazole in the presence or absence of PD-332991. Cells were then subjected to mitotic shake-off and replated in the presence or absence of PD-332991. (a) Cells were harvested for fluorescence-activated cell sorter (FACS) analysis at the indicated time points post-mitotic shake-off. (b and c) Cells were harvested and lysed at the indicated time points post-mitotic shakeoff. Proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE), and the indicated proteins were detected by immunoblotting. An asynchronous (Asynch.) population of U2OS cells is included for comparison. of S phase (Vaziri et al., 2003; Braden et al., 2006) . Thus, combined these findings indicate CDK inhibition has distinct implications on the replication apparatus.
The mechanism by which suppression of CDK4/6 activity impacts the cell cycle remains controversial. From genetic models, it is clear that deficiency of cyclin D-associated kinase activity can be tolerated, as cells from genetically modified mice deficient in D-type cyclins or CDK4/6 activity remain competent for proliferation (Kozar et al., 2004; Malumbres et al., 2004) . In this context, deletion of D-type cyclins or CDK4/6 allows for compensation by other CDK activities. This contrasts significantly with the pharmacological attenuation of CDK4/6 activity resulting in a reduction of CDK2 function and cell cycle arrest. Here we demonstrate that suppression of CDK4/6 activity is associated with a significant attenuation in CDK2 activity, which is dependent on the RB protein. Therefore, in an RB-proficient cell, CDK4/6 inhibition leads to the inhibition of CDK2 activity. The basis for this distinction between deletion and inhibition of kinase activity has not been clearly resolved. In the context of our study, the cyclin D TKO cells lack the target of PD-0332991. Correspondingly, because CDK2 is now mediating functions normally achieved by cyclin D-associated kinase activity, the downregulation of cdc6 and cdt1 is occurring as a consequence of inhibiting other kinase complexes. Combined these results suggest that the composite activity of CDK4/6 and CDK2 are overlapping in nature and support the assembly of pre-RC complexes.
The mechanism through which CDK activity impinges on cdt1 and cdc6 levels remains an area of intense study. Both cdt1 and cdc6 are E2F-regulated genes (Dyson, 1998; Hateboer et al., 1998; Markey et al., 2002; Yan et al., 1998) , and therefore their RNA levels can be modulated with the activation of the RB growth inhibitory pathway. In addition, cdt1 and cdc6 are also responsive to post-translation modifications and regulated turnover (Hateboer et al., 1998; Nguyen et al., 2001; Liu et al., 2004) . Specifically, cdt1 is ubiquitinated and degraded as cells progress through S phase in a Cul4a/PCNA-dependent fashion (Senga et al., 2006) . Interestingly, recent studies indicate that this degradation process is modulated by nuclear localization of cyclin D1, such that CDK4/6/cyclin D1 activity stabilizes cdt1 (Aggarwal et al., 2007 ). Here we demonstrate that inhibition of CDK4/6 in RB-proficient cells results in decreased cdc6 and cdt1 RNA levels, consistent with the idea that cdc6 and cdt1 are E2F regulated. In addition, treatment of cells with the proteosome inhibitor MG132 stabilizes the two proteins, indicating that cdc6 and cdt1 are relatively unstable in nature, a characteristic that enhances their downregulation in RB-proficient cells. In addition, the phosphorylation of cdc6 by CDK2 on three serine sites in the N-terminal domain is postulated to protect the protein from anaphase-promoting complex mediated degradation (Mailand and Diffley, 2005) . Whether CDK4 directly catalyses phosphorylation of these sites is not currently known, but provides a provocative potential target through which CDK4/6 and CDK2 could exert direct, yet redundant, control over the replication apparatus.
Presumably, the activity of CDK4/6 in facilitating pre-RC assembly could be critical in two distinct facets of cell cycle control. First, in asynchronous cells it is well appreciated that cyclin D1 is nuclear and present at high concentrations as cells progress from S phase into G 2 /M. Furthermore, the G 2 pool of cyclin D1 is required for mitogen-independent progression in a continuous cell cycle (Guo et al., 2002) . This accumulation of cyclin D1 could be particularly important for facilitating the loading of the pre-RC as cells exit mitosis. Such a function of cyclin D1 is consistent with our data that suggest inhibition of mitotic CDK4/6 activity prevents accumulation of cdc6 and cdt1, thus blocking pre-RC assembly. Second, as cells transition from quiescence into the cell cycle, the phosphorylation of RB, and subsequent activation of CDK2, is likely critical in enabling the synthesis of multiple factors involved in DNA replication. As such, targeting CDK4/ 6 activity acts through the RB pathway to influence DNA replication.
Accumulating evidence suggests that appropriate coordination of the DNA replication machinery is important for the suppression of tumorigenesis (Tanaka and Diffley, 2002; Vaziri et al., 2003) . Aberrant pre-RC assembly has been shown to induce re-replication and aneuploidy, and correspondingly, enforced expression of cyclin D1 or cyclin E influences the replication machinery to induce genome instability (Ekholm-Reed et al., 2004) . In this study, we demonstrate that targeted inhibition of CDK4/6 can prevent pre-RC assembly as a means to enforce cell cycle arrest. Although the specific mechanism for how G 1 -CDK activity in influencing DNA replication control remains the subject of ongoing research, the data presented herein provide new insight into specific roles for CDK4/6 in pre-RC assembly. Interestingly, CDK4/6 activity is frequently deregulated in cancer due to loss of p16ink4a or aberrant cyclin D1 expression. Thus, targeted inhibition of CDK4/6 may be particularly important for suppressing aberrant DNA replication and tumorigenesis.
Materials and methods
Cell culture, drug treatments, and synchronization U2OS and Saos-2 osteosarcoma cell lines were utilized due to the presence (U2OS) or absence (Saos-2) of functional RB. WT and cyclin D1, D2, D3-null immortalized murine fibroblasts were obtained from P Sicinski. Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin-streptomycin and 2 mM L-glutamine at 37 1C in 5% CO 2 . Cells synchronized in mitosis were treated with 50 ng/ml nocodazole (CalBiochem, La Jolla, CA, USA). To release the nocodazole block, cells were washed 3 Â with phosphatebuffered saline (PBS) and cultured in fresh media. Mitotic shake-off experiments were performed by incubating cells in nocodazole overnight, followed by perturbation of the culture plate and replating of mitotic cells into fresh media. Drug treatments were performed with dimethyl sulfoxide (DMSO; vehicle), 50 nM PD-332991 (Pfizer Corp., New York, NY, USA), 1 mM MG132 (Sigma, St Louis, MO, USA) and 10 mM roscovitine (CalBiochem) unless specified otherwise.
Viral transduction U2OS and Saos-2 cells were transduced with adenovirus expressing p16ink4a at an approximate multiplicity of infection of 10 for 24 h. Retrovirus encoding an shRB plasmid (murine stem cell virus (MSCV)-LMP Rb88; targeted sequence: 5 0 -GAAAGGACATGTGAACTTA-3 0 ) or control plasmid (MSCV donor) were utilized to create RB knockdown or control U2OS and IMR90 cell lines. Following selection with 2.5 mg/ml puromycin for 4 days, polyclonal cell lines were characterized.
Biochemical fractionation and western blotting
To analyse chromatin-bound proteins, the protocol from Fujita et al. (1996) was adapted. Cells were cultured in 15 cm plates, washed 3 Â with PBS, trypsinized and centrifuged at 5000 r.p.m. for 5 min at 4 1C. Soluble proteins were then extracted with ice-cold CSK buffer (10 mM (piperazine N, N-bis(2-ethanesulfonic acid) (PIPES), pH 6.8), 100 mM NaCl, 300 mM sucrose, 1 mM MgCl 2 , 1 mM EGTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride), supplemented with 0.1% Triton X-100 for 15 min at 4 1C. Extracted cells were centrifuged at 5000 r.p.m. for 5 min at 4 1C and the supernatant collected. Total cell extracts were harvested as previously described (Angus et al., 2004) . Lysates were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon-P membrane (Millipore, Bedford, MA, USA). Membranes were incubated with the following antibodies: Santa Cruz-anti-cyclin A (C19 mouse, H432 human), anti-cyclin D1, anti-cyclin D2, anti-cyclin D3, anti-b tubulin (D10), anti-PCNA (PC10), anti-MCM7 (141.2), anti-Lamin B (M20), anti-Cdc6 (180.2), anti-CDK2 (M2), anti-CDK4 (C22), anti-p27KIP1, anti-CDK1 (17), anti-RB (Ser780) (Cell Signaling, Danvers, MA, USA) and cyclin D1 (Neomarkers, Union City, CA, USA). Antibodies against RB (J Wang, University of California, San Diego, La Jolla, CA, USA) and Cdt1 (J Cook, University of North Carolina at Chapel Hill, NC, USA) were generous gifts.
RT-PCR
RNA was harvested from U2OS and Saos-2 cell cultures by using TRIzol according to the manufacturer's suggested protocols. Superscript reverse transcriptase (Invitrogen, Carlsbad, CA, USA) and 5 mg of total RNA were used to generate cDNAs with random hexamer primers. PCR was carried out using the following primers: 5 0 -GCGATGAC AACCTATGCAACACTC-3 0 and 5 0 -GATGACATCCATCT CCCTTTCCCT-3 0 (human cdc6), 5 0 -AAGGATCCCGCCT ACCAGCGCTTCC-3 0 and 5 0 -CCAAGCTTGAAGGTGGG GACACTG-3 0 (human cdt1), and 5 0 -GGTCATCAATGGGA AACCCATCAC-3 0 and 5 0 -AGTACTGGTGTCAGGTACG GTAGT-3 0 (glyceraldehyde-3-phosphate dehydrogenase, GAPDH). PCR conditions were as follows: 35 cycles (denaturation at 94 1C for 30 s, annealing at 57 1C for 30 s, elongation at 72 1C for 30 s) for cdc6 and cdt1, and 30 cycles (denaturation at 94 1C for 30 s, annealing at 53 1C for 30 s, elongation at 72 1C for 30 s) for GAPDH.
Immunofluorescence microscopy For PCNA and MCM7 staining, approximately 10 5 cells were seeded onto coverslips, washed with ice-cold PBS and fixed with methanol for 5 min. To visualize chromatin-tethered proteins coverslips were washed 3 Â with PBS and extracted with a modified CSK buffer as described above and fixed in ice-cold methanol for 5 min. The following antibodies were used for immunofluorescence: PCNA (PC-10 Santa Cruz) and MCM7 (141.2 Santa Cruz). Immunofluorescence data are from at least three independent experiments with at least 200 cells scored per experiment. BrdU incorporation assays were performed as previously described (Braden et al., 2006) .
Flow cytometry
Cells were harvested by trypsinization, fixed with ethanol and incubated with propidium iodide (PI) or PI and anti-BrdU FITC-conjugated secondary antibody. Histograms represent at least 10 000 events.
